Endocrinology Medical News about Diabetes Mellitus, Type 2 Taspoglutide

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
Diabetic Medicine, 11/10/09

Kapitza C et al. – Plasma concentrations peaked within 24 h after injection and were sustained for >= 14 days with all doses. In comparison with placebo, the 8– and 30–mg doses of taspoglutide significantly reduced glycaemic parameters, including 24–h blood glucose and 5–h postprandial glucose areas under the curve (AUCs), for up to 14 days with the 30–mg dose. The most common adverse events, primarily gastrointestinal in nature, were dose–dependent and transient. A single dose of taspoglutide significantly improved glycaemic parameters in Type 2 diabetes patients for up to 14 days. The formulation was well tolerated and appears suitable for weekly administration.

<< Previous
Resident Intimal Dendritic Cells Accumulate Lipid and Contribute...

Next >>
The threshold for definition of impaired fasting glucose in a...